Atlas Venture Opportunity Fund I, L.P.'s Net Worth

$471 Million

Who is Atlas Venture Opportunity Fund I, L.P.?

Atlas Venture Opportunity Fund I, L.P. has an estimated net worth of $471 Million. This is based on reported shares across multiple companies, which include Vigil Neuroscience, Inc., Day One Biopharmaceuticals, Inc., Dyne Therapeutics, Inc., Generation Bio Co., Akero Therapeutics, Inc., Replimune Group, Inc., Ikena Oncology, Inc., Kymera Therapeutics, Inc., Magenta Therapeutics, Inc., Disc Medicine, Inc., Xilio Therapeutics, Inc., AVROBIO, Inc., and Third Harmonic Bio, Inc..

SEC CIK

Atlas Venture Opportunity Fund I, L.P.'s CIK is 0001759241

Past Insider Trading and Trends

2021 was Atlas Venture Opportunity Fund I, L.P.'s most active year for acquiring shares with 13 total transactions. Atlas Venture Opportunity Fund I, L.P.'s most active month to acquire stocks was the month of May. 2021 was Atlas Venture Opportunity Fund I, L.P.'s most active year for disposing of shares, totalling 33 transactions. Atlas Venture Opportunity Fund I, L.P.'s most active month to dispose stocks was the month of November. 2022 saw Atlas Venture Opportunity Fund I, L.P. paying a total of $34,090,021.70 for 16,180,239 shares, this is the most they've acquired in one year. In 2023 Atlas Venture Opportunity Fund I, L.P. cashed out on 675,637 shares for a total of $34,351,525.03, their largest year based on trade value.